oasis 1 semaglutide Oral for Treatment of Obesity and Type 2 Diabetes—Results from and PIONEER PLUS Trial ADA Clinical Trial Talks: Oral

This is not fat

Buyer-aligned messaging should emphasize how each technology solves the users pain points lower cost of administration for hospitals, new biologic delivery pathways for pharma, and clinic-grade results for consumer brands ensuring clear product superiority in every segment

Furthermore, interventions associated with a reduced risk of cardiovascular disease as demonstrated in cardiovascular outcomes trials are preferred, particularly for patients at high risk of these events [7]

Read more at #DCAT #ValueChainInsights: To view or add a comment, sign in As the UK ponders its approach to medicines pricing and VPAG, it would be well advised to bear in mind this observation from the latest IQVIA Institute for Human Data Science report on Drug Expenditure Dynamics: "The UK has one of the highest generic substitution and biosimilar uptake rates in Europe